Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.59 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.50 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.49 |
| ▸ | HPGDS | O60760 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4965437 | 0.92 | PDE4B (0.57) | NAMPTP2RY14KMT2AGPR119KDM4E | |
| SCHEMBL8251243 | 0.89 | NAMPT (0.57) | NAMPTP2RY14KMT2AGPR119KDM4E | |
| SCHEMBL22564659 | 0.89 | GPR119 (0.67) | NAMPTP2RY14KMT2AGPR119KDM4E | |
| SCHEMBL229512 | 0.88 | NAMPT (0.58) | NAMPTP2RY14KMT2AGPR119KDM4E | |
| SCHEMBL6132207 | 0.88 | GPR119 (0.67) | NAMPTP2RY14KMT2AGPR119KDM4E | |
| SCHEMBL20046171 | 0.87 | KDM4E (0.50) | NAMPTP2RY14KMT2AGPR119KDM4E | |
| SCHEMBL3843148 | 0.87 | NAMPT (0.66) | NAMPTKMT2AGPR119KDM4EMAPT | |
| SCHEMBL1198897 | 0.86 | NAMPT (0.60) | NAMPTP2RY14KMT2AGPR119KDM4E | |
| SCHEMBL3854559 | 0.86 | NAMPT (0.61) | NAMPTP2RY14KMT2AGPR119KDM4E | |
| SCHEMBL12117456 | 0.86 | GPR119 (0.65) | NAMPTKMT2AGPR119KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 280 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111056990-B | Preparation method for synthesizing 1-tert-butyloxycarbonyl-4- (4-carboxyphenyl) piperidine | 爱斯特（成都）生物制药股份有限公司 | 2022-06-17 | — | — | CN | claimed |
| CN-111056990-A | Preparation method for synthesizing 1-tert-butyloxycarbonyl-4- (4-carboxyphenyl) piperidine | 爱斯特（成都）生物制药股份有限公司 | 2020-04-24 | — | — | CN | claimed |
| EP-4735452-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS PROTEIN | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| US-20260014147-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20260015338-A1 | TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4676922-A1 | BIFUNCTIONAL COMPOUNDS CAPABLE OF DEGRADING ANDROGEN RECEPTORS | Astrazeneca AB (SE) | 2026-01-14 | — | — | EP | disclosed |
| US-20260001893-A1 | SMALL MOLECULE MODULATORS OF STAT6 | GILEAD SCIENCES INC (US) | 2026-01-01 | — | — | US | disclosed |
| WO-2025262297-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| EP-4667467-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2025-12-24 | — | — | EP | disclosed |
| US-20250340551-A1 | SMALL MOLECULE MODULATORS OF STAT6 | GILEAD SCIENCES INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-12454521-B2 | Targeted protein degradation | C4 THERAPEUTICS, INC. | 2025-10-28 | — | — | US | disclosed |
| WO-1999000121-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1999-01-07 | — | — | WO | disclosed |
| US-5854245-A | Fibrinogen receptor antagonists | MERCK & CO., INC. (US) | 1998-12-29 | — | — | US | disclosed |
| WO-1998054164-A1 | SULFONAMIDE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-12-03 | — | — | WO | disclosed |
| US-5455348-A | Anticoagulants | Thomae, Karl (DE) | 1995-10-03 | — | — | US | disclosed |
| US-5442064-A | Anticoagulants, antiagglomerants | DR. KARL THOMAE GMBH (DE) | 1995-08-15 | — | — | US | disclosed |
| CN-1094035-A | Carboxylic acid derivative contains pharmaceutical composition of these compounds and preparation method thereof | THOMAE GMBH DR K (DE) | 1994-10-26 | — | — | CN | disclosed |
| EP-0604800-A1 | 4- 4- 4-(carboxyalkyl)-phenyl amino carbonyl -phenyl -piperedines as aggregation inhibitors | Dr. Karl Thomae GmbH (DE) | 1994-07-06 | — | — | EP | disclosed |
| CN-1087904-A | Carboxylic acid derivative, the pharmaceutical composition that contains these compounds with and preparation method thereof | KRAL THOMAE GMBH (DE) | 1994-06-15 | — | — | CN | disclosed |
| EP-0592949-A2 | N-(aminocarbonyl)-piperidines/pepirazines as aggregation inhibiting agents | Dr. Karl Thomae GmbH (DE) | 1994-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015338-A1 | TARGETED PROTEIN DEGRADATION | PSMC3, PSMA6, ADRM1 | NAMPT 4868/4885P2RY14 4781/4885KMT2A 2453/4885 |
| US-12454521-B2 | Targeted protein degradation | STUB1, MDM2, UBE3A | NAMPT 3483/4885P2RY14 4596/4885KMT2A 1131/4885 |
| US-20250340551-A1 | SMALL MOLECULE MODULATORS OF STAT6 | STAT6, STAT1, STAT5B | NAMPT 1103/4885P2RY14 2854/4885KMT2A 684/4885 |
| US-20260001893-A1 | SMALL MOLECULE MODULATORS OF STAT6 | STAT6, NCOR1, NCOR2 | NAMPT 3431/4885P2RY14 2244/4885KMT2A 1551/4885 |
| US-20260014147-A1 | STAT6 DEGRADERS | STAT6, NCOR1, CBR1 | NAMPT 4171/4885P2RY14 2087/4885KMT2A 2021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.